Drugs / Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04661397 | Jan → Jul 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04661397 ↗ |
| Known as | D/C/F/TAF | “Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a fixed-dose combination (FDC) for the treatment of HIV-1 infection in adults and...” PMID 37335552 ↗ Jun 2023 |
| Route | Oral | “Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.” NCT04661397 ↗ |